Physician profile
John W Eklund
NPI 1174510523
$17,429.86
in general payments reported to CMS, 2019-2025
86 companies · $2,827 in 2025
The $2,827 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,673 · 2020: $801 · 2021: $1,491 · 2022: $3,251 · 2023: $3,561 · 2024: $2,827 · 2025: $2,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,174 · Education: $41.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,173.77 |
| Education | $41.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,448.91 | 2019-2025 | |
| Pfizer INC. | $849.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $754.85 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $694.02 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Amgen INC. | $681.46 | 2019-2023 | Blincyto, Vectibix, Xgeva |
| Janssen Biotech, INC. | $621.83 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Celgene Corporation | $602.16 | 2019-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $590.21 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Seagen INC. | $534.94 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Eisai INC. | $519.37 | 2019-2025 | |
| Incyte Corporation | $508.00 | 2019-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $498.33 | 2019-2025 | Vyloy, Xospata, Padcev |
| Abbvie INC. | $492.74 | 2019-2025 | |
| Octapharma USA, INC. | $480.18 | 2019-2024 | Octagam Immune Globulin (Human), Panzyga |
| Genentech USA, INC. | $460.70 | 2019-2025 | Tecentriq, Alecensa, Polivy |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $430.90 | 2019-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $423.81 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $407.96 | 2019-2023 | Imbruvica |
| Gilead Sciences, INC. | $352.38 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $347.90 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.68 | 2019-2025 | |
| Lilly USA, LLC | $303.06 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Daiichi Sankyo INC. | $226.34 | 2019-2025 | Enhertu, Datroway |
| Adc Therapeutics America, INC. | $215.91 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $213.49 | 2020-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $197.81 | 2019-2023 | |
| Beigene USA, INC. | $187.86 | 2021-2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $186.46 | 2022-2025 | Besremi |
| Servier Pharmaceuticals LLC | $181.78 | 2021-2024 | |
| Agios Pharmaceuticals, INC. | $175.64 | 2022-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $167.46 | 2021-2025 | Qinlock |
| Emd Serono, INC. | $158.98 | 2022-2024 | Bavencio, Tepmetko |
| Janssen Pharmaceuticals, INC | $139.94 | 2019-2021 | |
| Tersera Therapeutics LLC | $139.08 | 2019-2025 | Zoladex, Xermelo |
| Aveo Pharmaceuticals, INC. | $138.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $137.33 | 2020-2025 | Zejula, Jemperli |
| G1 Therapeutics, INC. | $134.80 | 2022-2023 | Cosela |
| Ipsen Biopharmaceuticals, INC | $134.21 | 2019-2022 | |
| Array Biopharma INC | $124.14 | 2019-2025 | Braftovi, Lorbrena, Tukysa |
| Dendreon Pharmaceuticals LLC | $123.24 | 2024-2025 | Provenge |
| Alexion Pharmaceuticals, INC. | $121.48 | 2022-2024 | Ultomiris |
| Exelixis INC. | $119.65 | 2019-2024 | Cabometyx |
| Kite Pharma, INC. | $106.74 | 2020-2025 | Yescarta |
| Genmab U.S., INC. | $106.00 | 2023-2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.38 | 2019-2025 | Gilotrif |
| Tesaro, INC. | $82.61 | 2019 | |
| Rigel Pharmaceuticals, INC. | $77.50 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Amneal Pharmaceuticals LLC | $74.97 | 2024-2025 | Avastin, Alymsys |
| Stemline Therapeutics INC. | $74.34 | 2023-2025 | Orserdu |
| Sobi, INC | $73.68 | 2023-2025 | |
| Taiho Oncology, INC. | $68.27 | 2019-2025 | |
| Morphosys, US INC. | $61.55 | 2021-2023 | Monjuvi |
| Beone Medicines USA, INC. | $55.15 | 2025 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $52.37 | 2023-2024 | Rolvedon |
| Pharmacosmos Therapeutics INC. | $49.47 | 2024 | Cosela |
| Blueprint Medicines Corporation | $48.67 | 2023-2024 | Ayvakit |
| Verastem, INC. | $45.60 | 2019-2020 | |
| Eusa Pharma (US) LLC | $44.81 | 2022 | |
| Mirati Therapeutics, INC. | $43.84 | 2023-2024 | Krazati |
| Mylan Institutional INC. | $43.42 | 2020-2023 | Ogivri, Fulphila |
| Puma Biotechnology, INC. | $42.62 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $42.31 | 2019-2020 | |
| Fennec Pharmaceuticals, INC. | $42.31 | 2024 | Pedmark |
| Epizyme, INC. | $39.54 | 2023-2024 | Onivyde, Somatuline Depot |
| Kyowa Kirin, INC. | $39.31 | 2024-2025 | Poteligeo |
| Foundation Medicine, INC. | $38.75 | 2021-2022 | |
| Dova Pharmaceuticals | $35.68 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $35.58 | 2024 | |
| Syndax Pharmaceuticals, INC. | $28.62 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $27.74 | 2019 | |
| Emmaus Medical, INC. | $26.23 | 2023 | Endari |
| Geron Corporation | $24.31 | 2025 | Rytelo |
| Global Blood Therapeutics, INC. | $22.80 | 2022 | |
| Blue Earth Diagnostics | $21.65 | 2023 | |
| Clovis Oncology, INC. | $21.54 | 2022 | |
| Coherus Oncology, INC. | $20.90 | 2025 | Loqtorzi |
| Macrogenics, INC. | $20.83 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.42 | 2025 | Empaveli |
| Adaptive Biotechnologies Corporation | $19.95 | 2024 | Clonoseq |
| Immunocore Limited | $19.88 | 2025 | Kimmtrak |
| Azurity Pharmaceuticals, INC. | $19.29 | 2024 | Vivimusta |
| Acceleron Pharma, INC. | $19.22 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.76 | 2025 | Myrisk |
| Advanced Accelerator Applications | $14.95 | 2019 | |
| Melinta Therapeutics, LLC | $13.36 | 2023 | Rezzayo, Vabomere |
| Helsinn Therapeutics (U.S.), INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
Reblozyl $370Lenvima $327Octagam Immune Globulin (Human) $277Libtayo $250Enhertu $246Keytruda $235Adcetris $225Elrexfio $209Venclexta $205Xtandi $203Padcev $197Kisqali $180Epkinly $180Opdivo $175Imbruvica $159Scemblix $153Tukysa $153Besremi $150Brukinsa $147Fabhalta $145Darzalex $145Verzenio $138Calquence $138Monjuvi $136Jakafi $128Bosulif $123Provenge $123Lynparza $120Fotivda $119Cosela $118Tecvayli $114Iclusig $112Panzyga $112Tecentriq $111Pyrukynd $111Nubeqa $111Trodelvy $109Inlyta $105Ibrance $104Ultomiris $96.62Tibsovo $96.13Erleada $89.10Jemperli $87.86Zejula $87.86Vyloy $86.27Bavencio $86.12Braftovi $84.87Alunbrig $83.60Fruzaqla $82.25Qinlock $80.31Lorbrena $80.05Talzenna $79.79Pluvicto $77.56Zepzelca $75.22Orserdu $74.34Opdualag $73.25Zoladex $67.92Xospata $66.87Alecensa $65.78Enjaymo $64.98Cablivi $64.98Gavreto $63.36Piqray $62.99Tasigna $59.41Rezlidhia $58.69Tavalisse $58.69Rolvedon $52.37Mektovi $52.28Yescarta $50.87Besponsa $50.54Talvey $49.68Polivy $49.54Avastin $49.40Ayvakit $48.67Paxlovid $48.14Idhifa $48.04Elahere $47.64Lonsurf $46.11Inqovi $46.11Krazati $43.84Pedmark $42.31Lutathera $42.28Vitrakvi $40.54Stivarga $40.54Onivyde $39.54Somatuline Depot $39.54Poteligeo $39.31Vonjo $38.38Xermelo $35.97Odomzo $35.58Yonsa $35.58Doptelet $35.30Ninlaro $32.50Xpovio $31.44Emrelis $31.35Retevmo $30.79Datroway $26.44Endari $26.23Alymsys $25.57Akeega $25.53
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eklund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.